Mandate

VINGE ADVISED THE UNDERWRITERS IN RELATION TO NORDAX’S LISTING ON NASDAQ STOCKHOLM

June 22, 2015

Vinge advised Morgan Stanley & Co International plc, Carnegie Investment Bank AB (publ), Citigroup Global Markets Ltd and ABG Sundal Collier AB in relation to Nordax listing on Nasdaq Stockholm. Nordax’s principal shareholder is Vision Capital. A prospectus was published on 4 June 2015 and the first day of trading on Nasdaq Stockholm was on 17 June 2015. The price in the offering was set at SEK 45. The total value of the offering amounts to SEK 2.847 billion, assuming that the over-allotment option is exercised in full.

Nordax is a leading niche bank in the Nordic region providing unsecured consumer loans and deposit accounts to about 95,000 customers in Sweden, Norway, Finland, Denmark and Germany. As of 31 March 2015 lending to the general public amounted to SEK 10.3 billion and deposits amounted to SEK 6.5 billion.

Vinge’s team consisted mainly of responsible partner Charlotte Levin and associates Joakim Hagberg, Sabina Börjesson and Joel Wahlberg, and Axel Hedberg regarding regulatory questions.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026